In treating hematologic malignancies, engineered T-cell therapy outperforms standard transplantation with respect to chronic ...

The rate of cGVHD-free survival was 78% at 1 year in patients who received Orca-T compared with 38% among patients who ...

Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...

Cellogen Therapeutics’ CAR T cell technology introduces a bi-specific approach to cancer immunotherapy. Unlike conventional ...

Bi-Specific 3rd Generation CAR T therapy is a revolutionary advancement in cellular immunotherapy, primarily used to treat ...

Among the 13 CAR-T therapeutics that have received regulatory approval are Gilead’s Yescarta and Immuneel Therapeutics’ ...

This therapy targets multiple tumor-specific antigens, offering improved treatment precision for blood cancer patients, and ...

Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial ...

Using bacteria to fight cancer dates back to the 1860s when William B Coley, often called the father of immunotherapy, ...

The genetic modification of the Natural Killer (NK) cells, lymphocytes forming part of the body’s immune system, would make it possible to retain their capacity of eliminating tumour cells in solid ...

University of Queensland researchers are designing nanotechnology they believe could improve how we treat the most aggressive form of breast cancer.

Circadian rhythms are endogenous time-keeping mechanisms that regulate physiological processes in response to external ...